ArticleBMC neurology2026
Elevated platelet-activating factor levels predict complete brachial plexus injury: a retrospective case-control study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundObjective biochemical markers for stratifying brachial plexus injury (BPI) severity remain lacking. Platelet-activating factor (PAF), an inflammatory mediator implicated in neurological damage, has not been evaluated in traumatic BPI. We investigated whether serum PAF levels predict complete injury and correlate with nerve conduction impairment.
methodsThis retrospective case-control study analyzed 102 traumatic BPI patients (43 complete, 59 incomplete) and 51 matched controls enrolled between January 2020 and December 2023. Serum PAF and nerve conduction velocities (NCV) of median, radial, and ulnar nerves were measured. Multivariable logistic regression, restricted cubic spline (RCS) modeling, and ROC analysis were performed.
resultsBPI patients exhibited elevated PAF versus controls (171.8±26.1 vs. 147.7±12.1 pg/mL, P<0.001) and reduced mean NCV (19.8±2.6 vs. 64.0±6.1 m/s, P<0.001).PAF correlated inversely with NCV (ρ=-0.50, P<0.001). Complete injuries showed higher PAF (189.3±23.5 vs. 158.9±19.8 pg/mL, P<0.001) and lower NCV (all P<0.001). PAF (OR=1.151 per pg/mL, 95% CI: 1.033–1.284, P=0.011) and mean NCV (OR=0.012, P=0.014) independently predicted complete injury. RCS analysis revealed a nonlinear threshold at 165 pg/mL (OR=5.247, 95% CI: 2.808-9.803). PAF achieved good discrimination (AUC=0.840, sensitivity 84%, specificity 68%), though inferior to NCV (AUC=0.982). A multivariable model combining PAF, NCV, and injury-to-detection interval reached near-perfect discrimination (AUC=0.997).
conclusionsSerum PAF independently predicts complete BPI with a nonlinear threshold at 165 pg/mL. While electrophysiological assessment remains the gold standard, PAF demonstrates potential as a rapid, minimally invasive screening tool in acute settings where immediate nerve conduction studies are unavailable, particularly for triaging patients requiring urgent intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.